![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif)
recombinant MAGE-3.1 antigen A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE-expressing cells, resulting in antitumoral T cell-mediated cytotoxicity. MAGE-expressing cells are found in melanoma, non-small-cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, transitional cell carcinoma of the bladder, and esophageal carcinoma. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif) | MAGE-3 MAGE-3.1 MAGEA3 | | ![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif) |
Previous: | recombinant interleukin-3, recombinant interleukin-4, recombinant interleukin-6, recombinant interleukin-7, recombinant macrophage colony-stimulating factor | Next: | recombinant MAGE-A3 antigen-specific cancer immunotherapeutic GSK1203486A, recombinant modified vaccinia Ankara-5T4 vaccine, recombinant nematode anticoagulant protein c2, recombinant parathyroid hormone, recombinant platelet factor 4 |
|
![](https://webarchive.library.unt.edu/eot2008/20090513033510im_/http://www.cancer.gov/images/spacer.gif) |